Caraway Therapeutics is an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons. Co-founded by renowned biologists and industry veterans, the company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components. Caraway has a rigorous product engine with multiple approaches to potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative diseases. The company is backed by top-tier investors with world-class expertise in central nervous system diseases.
